Navigation Links
MEDRAD, Battelle Win Medical Design Excellence Award for MEDRAD XDS(TM) Extravasation Detector
Date:4/8/2008

Medical Design Excellence Awards is the Premier Award Program for Medical Technology

COLUMBUS, Ohio, April 8, 2008 /PRNewswire-USNewswire/ -- MEDRAD, Inc. and Battelle, the world's largest non-profit independent research and development organization, today announced the winning of a Medical Design Excellence Award (MDEA) for the MEDRAD XDS(TM) Extravasation Detector, a technology that enhances the safety of contrast media injection through early detection of extravasations. Extravasation is leakage of fluid, including contrast media, drugs, or solutions, from a vein into the surrounding tissue during intravenous administration.

The MDEA competition is a prestigious program recognizing medical product excellence and the achievements of medical product manufacturers (and the people who are responsible for groundbreaking innovations that are changing the face of healthcare). An impartial, multi-disciplinary panel of jurors with expertise in biomedical engineering, human factors, industrial design, medicine, and diagnostics reviewed the entries and selected the winners.

"We thank MD&DI for this prestigious MDEA that recognizes our XDS Extravasation Detector technology, the investment of many resources for research and development, and the inherent risk of developing medical devices; the MDEA validates that the investment and risk were worth it," said Cliff Kress, senior vice president, MEDRAD CT Business Unit. "We're also proud that we succeeded where others have not in developing an extravasation technology with a major impact on safety and a minor impact on workflow."

Battelle worked closely with MEDRAD to develop the technology from exploration through product development. MEDRAD and Battelle jointly invented the electrical permittivity technology that enables XDS(TM) and developed the commercial product.

XDS(TM) continuously monitors the tissue immediately surrounding and directly beneath the injection site for changes in relative permittivity signaling fluid accumulation.

"Battelle is pleased that our long-standing relationship with MEDRAD has yielded this breakthrough product," said Barbara Kunz, President, Battelle Health and Life Sciences Global Business. "Together, we have made a difference in patient safety and have improved the quality of care for patients undergoing imaging studies."

MEDRAD and Battelle will accept the award at a ceremony on June 4, 2008, at the Medical Design & Manufacturing (MD&M) East 2008 Conference and Exposition in New York City. Additionally, the MEDRAD XDS(TM) Extravasation Detector will appear with the other MDEA winners in the April 7 issue of Medical Device & Diagnostic Industry (MD&DI).

About Battelle

Battelle's Global Health and Life Sciences business delivers a comprehensive set of R&D services to solve complex challenges for government health agencies and medical device, biotechnology, and pharmaceutical firms. Including its national laboratories, Battelle oversees over $200 million annually in health and life sciences-research contributing to advances in medical devices, pharmaceuticals, public health, and next-generation diagnostics and therapeutics.

Battelle is the world's largest non-profit independent research and development organization, overseeing 20,000 employees in more than 130 locations worldwide, including five national laboratories Battelle manages or co-manages for the U.S. Department of Energy. Headquartered in Columbus, Ohio, Battelle conducts $4 billion in R&D annually through contract research, laboratory management, and technology commercialization. As a non-profit charitable trust with an eye toward the future, Battelle actively supports and promotes science and math education.


'/>"/>
SOURCE Battelle
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ventaira Pharmaceuticals Announces Acquisition of Assets by Battelle
2. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
3. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
4. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
5. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
6. BioMS Medical announces its intention to renew a normal course issuer bid
7. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
8. ATS Medical Expands Open Pivot Heart Valve Offerings
9. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
10. Globus Medical Announces Record 2nd Quarter 2007 Results
11. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks , ... industrial engineering, was today awarded as one of ... of the world,s most innovative companies. Ginkgo Bioworks ... for the real world in the nutrition, health ... work directly with customers including Fortune 500 companies ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Researchers at the ... commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject ... it now. , Diagnostic biomarkers are signposts in the blood, lung fluid or ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator ... Members of the Class of 2016 were selected from a pool of 128 ... About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):